Bifogade filer
Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies
Kurs
-0,33%
Likviditet
0,12 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2027-02-26 | 08:30 | Bokslutskommuniké 2026 |
| 2026-10-23 | 08:30 | Kvartalsrapport 2026-Q3 |
| 2026-08-20 | 08:30 | Kvartalsrapport 2026-Q2 |
| 2026-05-29 | N/A | X-dag ordinarie utdelning ICO 0.00 SEK |
| 2026-05-28 | N/A | Årsstämma |
| 2026-04-24 | 08:30 | Kvartalsrapport 2026-Q1 |
| 2026-02-12 | - | Bokslutskommuniké 2025 |
| 2025-12-15 | - | Extra Bolagsstämma 2025 |
| 2025-10-24 | - | Kvartalsrapport 2025-Q3 |
| 2025-07-14 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-28 | - | X-dag ordinarie utdelning ICO 0.00 SEK |
| 2025-05-27 | - | Årsstämma |
| 2025-04-24 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-27 | - | Bokslutskommuniké 2024 |
| 2024-10-29 | - | Extra Bolagsstämma 2024 |
| 2024-10-24 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-12 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-21 | - | Årsstämma |
| 2024-05-17 | - | X-dag ordinarie utdelning ICO 0.00 SEK |
| 2024-04-25 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-29 | - | Bokslutskommuniké 2023 |
| 2023-10-27 | - | Extra Bolagsstämma 2023 |
| 2023-10-27 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-14 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-23 | - | X-dag ordinarie utdelning ICO 0.00 SEK |
| 2023-05-22 | - | Årsstämma |
| 2023-04-28 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-10-28 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-15 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-19 | - | X-dag ordinarie utdelning ICO 0.00 SEK |
| 2022-05-17 | - | Årsstämma |
| 2022-04-29 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-18 | - | Bokslutskommuniké 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-20 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-20 | - | X-dag ordinarie utdelning ICO 0.00 SEK |
| 2021-05-19 | - | Årsstämma |
| 2021-04-29 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-17 | - | Bokslutskommuniké 2020 |
| 2020-10-27 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-19 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-11 | - | X-dag ordinarie utdelning ICO 0.00 SEK |
| 2020-05-08 | - | Årsstämma |
| 2020-05-08 | - | Kvartalsrapport 2020-Q1 |
| 2020-03-11 | - | Extra Bolagsstämma 2020 |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-10-25 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-16 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-16 | - | X-dag ordinarie utdelning ICO 0.00 SEK |
| 2019-05-15 | - | Årsstämma |
| 2019-04-25 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-11-09 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-10 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-16 | - | Årsstämma |
| 2018-04-19 | - | Kvartalsrapport 2018-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Iconovo AB (publ), which develops complete inhalation products for a global market, today announces that it has entered into a feasibility agreement with Affilogic, a French biotech company, regarding the implementation of a feasibility study of inhalable affinity proteins Nanofitins® in Iconovo's ICOone. The project aims to develop a new treatment for lung diseases.
Our new customer project adds additional value to Iconovo, with significant knowledge about the development of biological drugs, a growing market where we see great potential for our unique inhalers. We look forward to a close collaboration with Affilogic and have good hopes of being able to expand our collaboration in the future, says Johan Wäborg, CEO of Iconovo.
After the completion of the feasibility study, the biotech company has the opportunity to enter into a license agreement with Iconovo for the use of the treatment in one of the company's inhaler platforms with certain rights to exclusivity. Possible future license agreements may generate additional revenue through development work, milestone and royalty payments, or sales of inhalers.
About Iconovo
Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort® which is expected to reach the market in 2025. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Erik Penser Bank AB.